NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma, a clinical-stage biotech firm, is set to present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The company is known for its innovative approaches to treating nervous system damage and is currently evaluating its lead drug candidate, NVG-291, in clinical trials for spinal cord injury.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
